Bal Pharma Ltd - Stock Valuation and Financial Performance

BSE: 524824 | NSE: BALPHARMA | Pharmaceuticals & Drugs | Small Cap

Bal Pharma Share Price

98.05 3.60 3.81%
as on 21-Feb'25 16:59

DeciZen - make an informed investing decision on Bal Pharma

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Bal Pharma stock performance -
98.05 -19.00-16.00% past year

Price Chart, Live Stock Chart, Technical Chart of
P/E Ratio (SA):
15.12
Market Cap:
156.1 Cr.
52-wk low:
88.5
52-wk high:
157.9

Is Bal Pharma Ltd an attractive stock to invest in?

1. Is Bal Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bal Pharma Ltd is a below average quality company.

2. Is Bal Pharma Ltd undervalued or overvalued?

The key valuation ratios of Bal Pharma Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Bal Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bal Pharma Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bal Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE %
11.3%10.1%12.8%11.8%10%2.1%12.6%12.3%10.4%12%-
Value Creation
Index
-0.2-0.3-0.1-0.2-0.3-0.9-0.1-0.1-0.3-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales
187198226208223171249280303339315
Sales YoY Gr.
-5.6%14.3%-8.1%7.4%-23.5%46.1%12.5%8.1%11.7%-
Adj EPS
2.81.72.33.54.6-6.674.44.56.96.5
YoY Gr.
--41.1%41.8%51.3%29.7%-243.6%NA-37.1%1.1%54.4%-
BVPS (₹)
41.642.5475154.246.552.957.760.366.467.8
Adj Net
Profit
3.62.13.356.5-9.310.46.5710.910
Cash Flow from Ops.
14.41.36.412.611.621.710.230.65.429-
Debt/CF from Ops.
3.454.611.77.29.14.610.23.223.34.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.8%8.7%10.7%11.7%
Adj EPS 10.5%8.4%-0.6%54.4%
BVPS5.3%4.1%7.9%10.1%
Share Price 5% 20.7% -0.9% -16.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
6.83.85.47.28.7-13.114.37.87.610.89.7
Op. Profit
Mgn %
9.48.78.9119.24.211.48.49.29.910.3
Net Profit
Mgn %
1.91.11.52.42.9-5.54.22.32.33.23.3
Debt to
Equity
0.91.31.11.31.41.51.31.21.31.3-
Working Cap
Days
193211221290303386270273296289151
Cash Conv.
Cycle
727178112129179106961029739

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 9.70%

Sales growth is growing at healthy rate in last 3 years 10.74%

Net Profit has been subdued in last 3 years -0.62%

Debt to equity has increased versus last 3 years average to 1.28

Sales growth is not so good in last 4 quarters at -2.51%

Latest Financials - Bal Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 6.5 4.6
TTM Sales (₹ Cr.) 315 316
BVPS (₹.) 67.8 43.5
Reserves (₹ Cr.) 92 53
P/BV 1.45 2.25
PE 15.12 21.52
From the Market
52 Week Low / High (₹) 88.50 / 157.90
All Time Low / High (₹) 1.60 / 167.90
Market Cap (₹ Cr.) 156
Equity (₹ Cr.) 15.9
Face Value (₹) 10
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 94.6 15.473.1 4.274.7 -19.172.9 -10.6
Adj EPS (₹) 3.9 191.91.1 46.10.8 -25.50.7 -8.8
Op. Profit Mgn % 10.91 82 bps9.67 -8 bps10.01 172 bps10.60 124 bps
Net Profit Mgn % 6.58 399 bps2.39 69 bps1.61 -13 bps1.58 4 bps

Management X-Ray of Bal Pharma:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:50.86%Institutions:0.14%Non-Institutions:49%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%10%20%30%40%50%60%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Bal Pharma

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Bal Pharma

Adj EPS (Rs.)

Price Chart, Live Stock Chart, Technical Chart of

Sales (Cr.)

Price Chart, Live Stock Chart, Technical Chart of

ROE (%)

Price Chart, Live Stock Chart, Technical Chart of

ROCE (%)

Price Chart, Live Stock Chart, Technical Chart of
Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Alembic Pharma 802.8 -10.6 (-1.3%) Small Cap 6,229 30.8 9.6 26.4 3.2
Laurus Labs 521.1 -15.4 (-2.9%) Small Cap 5,041 3.7 3.1 144.5 6.9
Piramal Pharma 208.6 -9.5 (-4.3%) Small Cap 4,390 5.2 8.4 42.1 4.1
Ajanta Pharma 2,607.3 -63.1 (-2.4%) Small Cap 4,209 71.9 19 37.2 8.5
Gland Pharma 1,524.3 3.9 (0.3%) Small Cap 4,167 68.1 24.8 22.3 2.7
Natco Pharma 797.8 4.8 (0.6%) Small Cap 3,999 104.1 34.5 7.6 2
Granules India 509 -18.4 (-3.5%) Small Cap 3,755 13.3 11.7 39.7 3.9
Emcure Pharma 996.8 5.2 (0.5%) Small Cap 3,498 8.5 4.4 116.8 6.5
JB Chem & Pharma 1,605.5 -25 (-1.5%) Small Cap 3,299 40.4 16.1 40.4 7.7
Sanofi India 5,076.8 -91.3 (-1.8%) Small Cap 2,851 184.4 20.8 28 15.5
Shows rows:

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales187198226208223171249280303339
Operating Expenses 170181206185203164223257277306
Manufacturing Costs25242724272124324142
Material Costs87941048810476140153156176
Employee Cost 32364150484940445256
Other Costs 25273323241819282832
Operating Profit 1817202320727232633
Operating Profit Margin (%) 9.4%8.7%8.9%11.0%9.2%4.1%10.6%8.4%8.7%9.6%
Other Income 1132343623
Interest 7689131312111315
Depreciation 7767677778
Exceptional Items 0000000000
Profit Before Tax 55984-91012912
Tax 1233-201322
Profit After Tax 43567-999610
PAT Margin (%) 2.1%1.4%2.4%2.9%3.0%-5.2%3.6%3.1%2.0%3.0%
Adjusted EPS (₹)3.12.23.84.24.8-6.36.15.83.96.5
Dividend Payout Ratio (%)32%46%27%24%21%0%16%17%26%18%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 545567727766788595105
Share Capital 13131414141415151616
Reserves 41425258635264717989
Minority Interest0000000000
Debt4766708497949992117126
Long Term Debt7161835292324273136
Short Term Debt40505249687175658790
Trade Payables38475450473949729190
Others Liabilities 25262945364036404540
Total Liabilities 164193219251257239262290348361

Fixed Assets

Gross Block96106667176828692107117
Accumulated Depreciation4450613192633394453
Net Fixed Assets52566058575653536365
CWIP 1420000100
Investments 11077788816
Inventories36425466706860749887
Trade Receivables455761646652697895103
Cash Equivalents 54544345713
Others Assets25293751535367707676
Total Assets 164193219251257239262290348361

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 14161312221031529
PBT 55984-91012912
Adjustment 12111515161717141920
Changes in Working Capital -1-14-16-10-614-176-222
Tax Paid -1-1-1-1-200-1-1-5
Cash Flow From Investing Activity -6-14-8-16-12-3-7-13-22-18
Capex -5-14-8-4-5-4-3-8-15-10
Net Investments 0000-20-1-1-1-9
Others -100-12-50-3-5-71
Cash Flow From Financing Activity -712240-20-3-1717-8
Net Proceeds from Shares 0000003041
Net Proceeds from Borrowing 010017-5-90346
Interest Paid -7-6-8-9-12-12-12-10-12-15
Dividend Paid -2-2-2-2-1-10-1-2-2
Others 11012-31935-8232
Net Cash Flow 20010-10003
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)7.95.188.768.569.07-12.4712.6110.476.810.3
ROCE (%)11.310.0712.7711.769.952.0912.5712.2810.411.95
Asset Turnover Ratio1.21.131.130.890.880.6911.020.950.96
PAT to CFO Conversion(x)3.50.331.22.171.71N/A1.113.440.832.9
Working Capital Days
Receivable Days8792931091061258996104107
Inventory Days6570761051111479387103100
Payable Days150166176215171209114144191188

Bal Pharma Ltd Stock News

Bal Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bal Pharma on 21-Feb-2025 16:59 is ₹98.05.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Feb-2025 16:59 the market cap of Bal Pharma stood at ₹156.1.
The latest P/E ratio of Bal Pharma as of 21-Feb-2025 16:59 is 15.12.
The latest P/B ratio of Bal Pharma as of 21-Feb-2025 16:59 is 1.45.
The 52-week high of Bal Pharma is ₹157.9 and the 52-week low is ₹88.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bal Pharma is ₹315.3 ( Cr.) .

About Bal Pharma Ltd

Bal Pharma Limited is a leading Indian Pharmaceutical Company with 25+ years of experience, specialized in Prescription Drugs, Generic & OTC Products, Intravenous Infusion and Bulk Actives.

The company strives hard to improve the quality of life for patients by providing them products that are Safe, Effective, High Quality and Affordable.

The company’s API and FDF are produced at world class manufacturing facilities. APIs are largely exported to Europe, Far East, Latin America, Africa, Middle East and other World markets. The FDF are exported to Semi-Regulated, Non-Regulated market and are now foraying to regulated market. The company is also one of the strong contenders for World Tender Business.

Business area of the company

The company is engaged in the manufacturing and selling of pharmaceutical products. The company caters to both domestic and international markets.

Business segments

API Intermediate: The company’s API (Active Pharmaceutical Ingredients) business began in 1996 with a simple objective of facilitating the manufacture of niche molecules that have been able to take the benefits of vertical integration to international and domestic markets. Bal Pharma’s API business has the competence and knowledge to undertake more than 30 different types of complex chemical reactions.

Finished formulations: Bal Pharma has a winning formula of cutting edge technology, handled by a highly qualified professional with a passion to deliver beyond excellence. The company is successfully exporting Finished Formulation to many countries. The company offers extensive range of products covering dosage forms - tablets, capsules, syrups, suspensions, IV infusions, Ophthalmic, creams and ointments to various Semi-Regulated markets.

Ayurveda/Herbal: Ayurveda is India’s traditional, natural system of medicine that has been practiced for more than 5,000 years. Ayurveda is a Sanskrit word that, when literally translated, means 'science of life' or 'practices of longevity.' Ayurveda provides an integrated approach to preventing and treating illness through lifestyle interventions and natural therapies. The company’s objective of providing “Good life to All” launched its Ayurvedic Division - Bal Vedics in 2003. Bal Vedics is dedicated to bringing out ‘nature’s best’ through International Quality Natural Formulations that combine traditional Indian Wisdom of medicine with Scientific Manufacturing.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on